Advancing our understanding of feline HCM through protein resrarch
New Research Explores Potential Blood Protein Biomarkers for Feline HCM
Feline Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is the most common form of heart disease in cats, affecting an estimated 1 in 7 cats. In some cats, HCM remains subclinical, meaning that they show no outward signs of the disease, while in others, the disease can progress and lead to serious complications such as congestive heart failure, heart rhythm abnormalities, or feline arterial thromboembolism (FATE), commonly known as a saddle thrombus when it occurs near the hind limbs. Saddle thrombus is a veterinary emergency where a blood clot becomes lodged in an artery blocking blood flow and oxygen, causing severe pain and paralysis of the hind legs.
Because many cats show no outward signs of disease until HCM is advanced, researchers continue to search for ways to better understand the condition and identify affected cats earlier. A recent study by Ravuri et al., published in March 2026 in the journal Animals, investigated whether cats with HCM have a different pattern of proteins circulating in their blood compared with healthy cats. Understanding how protein expression differs between healthy cats and cats with HCM can help researchers better understand disease progression and identify potential biomarkers for early detection. For example, if we know that certain proteins are present in the blood of cats with HCM, scientists may be able to design tools to detect them early on. Scientists will also be able to which biological pathways are involved that may become targets for potential therapies. Although downstream applications such as biomarker detection assays and therapeutic development often require extensive research and development, knowing which proteins are differentially expressed in cats with HCM is the first step.
How Was the Study Conducted?
The researchers enrolled 20 cats: 10 diagnosed with HCM and 10 healthy control cats. Blood samples were collected from all cats and analyzed using an advanced laboratory technique that can measure hundreds of proteins simultaneously.
Rather than focusing on a single protein, the researchers compared the overall “protein fingerprint” of healthy cats and cats with HCM. Their goal was to identify proteins and biological pathways that differed between the two groups and might provide new insights into how HCM develops.
What Did the Researchers Find?
The study identified 40 proteins that differed significantly between healthy cats and cats with HCM. Many of these proteins were involved in several important biological processes, including:
• Inflammation
• Immune system activation
• Blood clotting and clot breakdown
• Regulation of blood pressure and cardiovascular function
One notable finding was evidence of increased activity in the complement system, a component of the immune system that helps the body respond to injury and infection. The complement system consists of a series of proteins that circulate around the blood until they become activated. Once activated, they initiate a chain reaction that fights off pathogens, triggers inflammation, and enhances tissue repair. Multiple complement-related proteins were elevated in cats with HCM.
The researchers also found changes in proteins involved in coagulation and fibrinolysis, providing potential targets for understanding why cats with HCM are susceptible to FATE. This finding is particularly important because blood clots are among the most devastating complications of feline HCM.
What Does This Mean?
The findings of this study support a growing body of research suggesting that HCM is a systemic, complex process that involves more than thickening of the heart muscle alone. Changes in proteins involved in inflammation, immune-signaling, and clotting pathways indicate that HCM may involve biological processes throughout the body. It is imported to note that future studies are needed to determine if inflammatory and immune-related changes contribute to the development of hypertrophic cardiomyopathy, if they occur as a consesquence of the structural damage in the heart, or a combination of both.
The finding of specific proteins that are dysregulated in the blood offers hope for potential early diagnostic tests and future therapeutic targets. However, it is important to understand that careful, rigorous, reproducible research takes time. Further investigation into the role of each of these proteins in feline HCM is needed, as well as additional studies involving larger numbers of cats before downstream applications of the research come to fruition.
Looking Toward the Future
While echocardiography remains the gold standard for diagnosing HCM, studies like this one are helping researchers better understand the biology of the disease. Future research may determine whether some of these protein changes occur early in the disease process, potentially before structural changes become apparent on an echocardiogram.
Researchers may also investigate whether specific protein patterns differ between cats with mild, moderate, and severe HCM, or whether these proteins can help predict which cats are at greatest risk of developing complications such as heart failure or blood clots.
Although much work remains to be done, this study provides an intriguing glimpse into the complex biological changes associated with feline HCM and highlights promising areas for future research.
Reference:
Ravuri HG, Daley AL, Silva P, McGreevy PC. Plasma Proteomic Profiling Identifies Potential Biomarkers and Pathophysiological Mechanisms in Feline Hypertrophic Cardiomyopathy. Animals. 2026;16:781.
Link to the research paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC12984393/
